One of the most relevant brands among our more than 25 partners is TargetMol

<p>RS 42358-197 (RS 25259-007) is a competitive 5-HT3 receptor antagonist.</p>

CS-VIP 8 TFA is a selective allosteric inhibitor of the WDR5 protein (Ki= 0.008 μM). It induces a conformational change in the MLL1 complex, leading to the dissociation of MLL1 from the complex, thereby inhibiting the MLL1 histone methyltransferase activity and modulating HOX gene expression. CS-VIP 8 TFA shows potential for research in hematological disorders such as leukemia.

Succinate dehydrogenase-IN-8 (compound i19) is a potent inhibitor of succinate dehydrogenase (SDH). This indanoyl amino acid derivative demonstrates strong antifungal activity in vitro against Rhizoctonia solani (EC50 = 0.1843 mg/L), Botrytis cinerea (EC50 = 0.4829 mg/L), and Sclerotinia sclerotiorum (EC50 = 0.1349 mg/L).

<p>Subquinocin is a CYLD inhibitor that suppresses deubiquitinating enzymes (DUB) of the USP family. By inhibiting CYLD, Subquinocin enhances the activation of the NF-κB and IFN pathways. Additionally, Subquinocin facilitates the activation of IRF3 and/or IRF7 in the RIG-I-mediated interferon pathway.</p>

<p>B-Raf inhibitor 1 (B-Raf inhibitor 1) is a potent and selective B-Raf inhibitor.</p>

<p>PROTACPI3K/110β degrader-1 (J-9) acts as a PROTAC degrader specifically targeting PI3K/110β.</p>

<p>BuChE-IN-21 (compound SXF3) is a potent and selective inhibitor of BuChE, demonstrating inhibitory effects on eqBuChE and hBuChE with IC50 values of 0.05 and 0.04 μM, respectively. Additionally, BuChE-IN-21 exhibits significant anti-inflammatory activity.</p>

<p>Tubulin inhibitor 50 (compound 07) is a microtubule protein inhibitor that enhances mitochondrial reactive oxygen species levels. It exhibits anticancer activity in HeLa cells with an IC50 value of 0.46 μM, while showing low toxicity in normal cell lines.</p>

<p>PD-M6 is an mTOR PROTAC degrader with a DC50 of 4.8 μM, which facilitates the ubiquitination and degradation of mTOR. It inhibits the proliferation of cancer cell lines HeLa, MCF-7, and HepG2 with IC50 values of 11.3, 2.58, and 3.23 μM, respectively, and induces autophagy. Additionally, PD-M6 specifically targets the degradation of the key protein LAMTOR1 in the mTOR signaling pathway.</p>

<p>Keap1/Nrf2/ARE activator 1 (compound HT-3) functions as an activator of the Keap1/Nrf2/ARE pathway. This compound has antioxidant properties and offers neuroprotective effects.</p>

Lilial, also lysmeral or butylphenyl methylpropional, is a lily-scented perfume ingredient in cosmetics and laundry detergents.

Lufironil (HOE 077) is an inhibitor of prolyl 4-hydroxylase, designed for investigating chronic liver conditions such as alcoholic hepatitis and cirrhosis.

STING ligand-4 (Compound 2) is a nitro-free covalent STING inhibitor with an IC50 of less than 0.2 μM. It can be utilized in the synthesis of PROTACSTINGdegrader-4.

HLDA-212 (Compound 43) is a bifunctional small molecule designed to target HaloTag-tagged protein (target protein, TP) and Aurora kinase A/B (AURKA/B, effector protein, EP). By binding TP and EP, it forms a stable ternary complex (TP:RIPTAC:EP) that inhibits the cell survival functions of EP, inducing apoptosis in cancer cells expressing TP. In 293_HFL cells, HLDA-212 demonstrates antiproliferative activity with a GI50 of 0.011 μM. This compound holds promise for treating cancers with high TP expression, such as prostate cancer and hematological malignancies.

FGT-4 is a chimeric molecule targeting folate receptor β (FR-β) and functions as a TLR7 agonist. It enhances the secretion of iNOS and the pro-inflammatory cytokine IL-6 associated with M1 macrophages and promotes the proliferation of cytotoxic CD8+ T cells. FGT-4 demonstrates antitumor activity in the 4T1 breast cancer mouse model and is applicable for cancer immunotherapy research.

<p>Amyloid-β-IN-2 (Compound EX.112) is a selective inhibitor of γ-secretase. In H4 cells, it demonstrates inhibitory activity on Aβ42 secretion, with an EC50 value of 226 nM. Amyloid-β-IN-2 holds potential for research in Alzheimer's disease (AD) and diseases associated with Aβ deposition.</p>

SP-C01 is an orally active soluble epoxide hydrolase (sEH) inhibitor and a partial agonist of PPARγ. It can inhibit the phosphorylation of Ser273.

<p>TG-89 is an inhibitor of JAK2, JAK3, RET and FLT3, and has an IC50 value of 11.2 μM against JAK2, showing anticancer activity in the treatment of ovarian and</p>

8-Sulfamoyloctanoic acid serves as a PROTAC linker employed in the synthesis of PROTACXZ338.

(R)-STU104-d6 is a deuterium-labeled variant of (R)-STU104. This compound acts as a potent and orally active inhibitor of the interaction between TAK1 and MKK3 proteins, exhibiting IC50 values of 0.58 μM for TNF-α and 4.0 μM for MKK3 phosphorylation. By binding to MKK3, (R)-STU104 hinders TAK1's ability to phosphorylate MKK3, thereby disrupting the TAK1/MKK3/p38/MnK1/MK2/elF4E signaling pathway. It is utilized in research related to ulcerative colitis.